These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 28485058)

  • 1. Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia.
    Lee YC; Kroon R; Koczwara B; Haines I; Francis K; Millward M; Kefford R; Olver I; Mileshkin L
    Intern Med J; 2017 Aug; 47(8):888-893. PubMed ID: 28485058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions between physicians and the pharmaceutical industry: what does the literature say?
    Lexchin J
    CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do doctors rely on pharmaceutical industry funding to attend conferences and do they perceive that this creates a bias in their drug selection? Results from a questionnaire survey.
    Rutledge P; Crookes D; McKinstry B; Maxwell SR
    Pharmacoepidemiol Drug Saf; 2003 Dec; 12(8):663-7. PubMed ID: 14762982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgeon-industry conflict of interest: survey of opinions regarding industry-sponsored educational events and surgeon teaching: clinical article.
    DiPaola CP; Dea N; Dvorak MF; Lee RS; Hartig D; Fisher CG
    J Neurosurg Spine; 2014 Mar; 20(3):313-21. PubMed ID: 24359001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical industry financial support for medical education: benefit, or undue influence?
    Brody H
    J Law Med Ethics; 2009; 37(3):451-60, 396. PubMed ID: 19723256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The medical-industrial complex, professional medical associations, and continuing medical education.
    Schofferman J
    Pain Med; 2011 Dec; 12(12):1713-9. PubMed ID: 22145759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study.
    Parker L; Fabbri A; Grundy Q; Mintzes B; Bero L
    BMJ; 2019 Dec; 367():l6694. PubMed ID: 31831471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations.
    Kerridge I; Maguire J; Newby D; McNeill PM; Henry D; Hill S; Day R; Macdonald G; Stokes B; Henderson K
    Intern Med J; 2005 Apr; 35(4):206-10. PubMed ID: 15836497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survey of Australasian geriatricians' satisfaction with, and preferences for, continuing professional development.
    Etherton-Beer C; Katz B; Naganathan V;
    Intern Med J; 2016 Jul; 46(7):805-11. PubMed ID: 27087018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuing medical education and pharmaceutical industry involvement: An evaluation of policies adopted by Canadian professional medical associations.
    Shnier A; Lexchin J
    Int J Risk Saf Med; 2017; 29(1-2):1-16. PubMed ID: 28885217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuing medical education: ethical collaboration between sponsor and industry.
    Wilson FS
    Clin Orthop Relat Res; 2003 Jul; (412):33-7. PubMed ID: 12838049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conflict of interest among Italian medical oncologists: a national survey.
    DeCensi A; Numico G; Ballatori E; Artioli F; Clerico M; Fioretto L; Livellara V; Ruggeri B; Tomirotti M; Verusio C; Roila F;
    BMJ Open; 2018 Jun; 8(6):e020912. PubMed ID: 29961019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers.
    Halperin EC; Hutchison P; Barrier RC
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1477-83. PubMed ID: 15275735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuing medical education and pharmaceutical industry.
    Vakani FS; Jafri W; Amin A; Sheerani M
    J Coll Physicians Surg Pak; 2011 Jun; 21(6):360-1. PubMed ID: 21711993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How do health consumer organisations in Australia manage pharmaceutical industry sponsorship? A cross-sectional study.
    Lau E; Fabbri A; Mintzes B
    Aust Health Rev; 2019 Aug; 43(4):474-480. PubMed ID: 30021681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Industry funding for continuing medical education: is it ethical?
    Heaphy DP; Marrow VB
    Arch Ophthalmol; 2004 May; 122(5):771-3. PubMed ID: 15136327
    [No Abstract]   [Full Text] [Related]  

  • 17. Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest.
    Rose SL; Highland J; Karafa MT; Joffe S
    JAMA Intern Med; 2017 Mar; 177(3):344-350. PubMed ID: 28114624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologist provision of smoking cessation support: A national survey of Australian medical and radiation oncologists.
    Day FL; Sherwood E; Chen TY; Barbouttis M; Varlow M; Martin J; Weber M; Sitas F; Paul C
    Asia Pac J Clin Oncol; 2018 Dec; 14(6):431-438. PubMed ID: 29706029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Australian medical radiation practitioners perspectives of continuing professional development: An online cross-sectional study.
    Morgan T; Ku M; Berg M; Halkett GK
    J Med Radiat Sci; 2023 Sep; 70(3):270-282. PubMed ID: 37301987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinician attitudes about commercial support of continuing medical education: results of a detailed survey.
    Tabas JA; Boscardin C; Jacobsen DM; Steinman MA; Volberding PA; Baron RB
    Arch Intern Med; 2011 May; 171(9):840-6. PubMed ID: 21555662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.